Publication | Open Access

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Hematological MalignancyCommon Anti-myeloma DrugsSignificant Anti-myeloma ActivityMedicinePharmacologyAnti-cancer AgentOncologyRadiation OncologyCancer Research